---
schema_version: "secwatch.filing_event.v1"
accession: "0001326110-26-000036"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2026-04-09T23:59:59+00:00"
generated_at: "2026-05-15T06:45:56.147503+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio reports preliminary Q1 2026 net product revenue $44.2M, up 168% YoY, cash $381M

## Summary
- Preliminary Q1 2026 net product revenue ~$44.2M, up 168% YoY and 15% sequentially from $38.3M in Q4 2025.
- Cash, cash equivalents and marketable securities of $380.9M as of March 31, 2026.
- ANKTIVA unit sales volume increased 168% YoY; now approved in 5 jurisdictions covering ~34 countries.
- NCCN guidelines updated March 2026 to include ANKTIVA plus BCG for BCG-unresponsive NMIBC papillary-only disease (Category 2A).
- Pivotal BCG-naive NMIBC CIS trial (QUILT-2.005) fully enrolled; supplemental BLA submission on track for 2026.

## SEC filing metadata
- accession: 0001326110-26-000036
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2026-04-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000132611026000036/0001326110-26-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000132611026000036/ibrx-20260409.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326110-26-000036
- JSON: https://secwatch.observer/filing/0001326110-26-000036.json
- Plain text: https://secwatch.observer/filing/0001326110-26-000036.txt

## Key facts
- Earnings Releases
  ImmunityBio, Inc. reported the fiscal quarter ending March 31, 2026 results: revenue approximately $44.2 million.
  - Period: the fiscal quarter ending March 31, 2026
  - Revenue: approximately $44.2 million
  - Result: preliminary results
  source text: ImmunityBio reported preliminary net product revenue of approximately $44.2 million during the three-month period ending March 31, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326110/000132611026000036/0001326110-26-000036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.